Involvement of the sigma(1) receptor in cocaine-induced conditioned place preference: possible dependence on dopamine uptake blockade

Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
P RomieuT Maurice

Abstract

The involvement of the sigma(1) receptor on the rewarding effects of cocaine was examined using the conditioned place preference (CPP) procedure in C57BL/6 mice. Acquisition or expression of cocaine (20 mg/kg i.p.)-induced CPP was significantly decreased by pre-treatment with the selective sigma(1) receptor antagonists N,N-dipropyl-2-(4-methoxy-3-(2-phenylethoxy)phenyl)ethylamine (NE-100) or N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(dimethylamino)ethylamine (BD1047), 1-10 mg/kg, i.p. The sigma(1) receptor agonists igmesine or 2-(4-morpholinoethyl-1-phenylcyclohexane-1-carboxylate hydrochloride (PRE-084) failed to induce CPP when injected alone. Moreover, the CPP induced by N-[1-(2-benzo(b)thiophenyl)cyclohexyl]piperidine (BTCP), a selective dopamine reuptake inhibitor, was blocked by treatments with the sigma(1) receptor antagonists as was similarly observed with cocaine. In addition, the repetitive treatment with cocaine during conditioning increased sigma(1) receptor mRNA expression in the nucleus accumbens, but not in the caudate putamen, prefrontal cortex or cerebellum. These data show that the sigma(1) receptor is not only necessary for acquisition of the cocaine-induced CPP, but that it is also implicated in its express...Continue Reading

Citations

Nov 28, 2007·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Guy A Cabral
May 14, 2003·European Journal of Pharmacology·Jonathan L KatzAmy Hauck Newman
Jun 5, 2003·European Journal of Pharmacology·Rae R MatsumotoDaniel J Brackett
Apr 2, 2003·Pharmacology, Biochemistry, and Behavior·Tangui MauricePascal Romieu
Sep 3, 2002·Neuroscience and Biobehavioral Reviews·Tangui MauriceRae R Matsumoto
Apr 12, 2011·Journal of Medicinal Chemistry·Agostino MarrazzoGiuseppe Ronsisvalle
Feb 25, 2005·Behavioral Neuroscience·Anita J Bechtholt, Christopher L Cunningham
Oct 24, 2008·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Valentina SabinoEric P Zorrilla
Feb 25, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Valentina SabinoEric P Zorrilla
Nov 29, 2012·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Takato HiranitaJonathan L Katz
Jun 21, 2012·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Pietro CottoneValentina Sabino
Sep 1, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Pascal RomieuTangui Maurice
Feb 3, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Rémi Martin-FardonFriedbert Weiss
May 25, 2002·The European Journal of Neuroscience·Vân-Ly PhanTangui Maurice
Mar 16, 2007·Proceedings of the National Academy of Sciences of the United States of America·Rossella VenturaStefano Puglisi-Allegra
Aug 3, 2011·Behavioural Pharmacology·Takato HiranitaJonathan L Katz
Nov 7, 2009·The Journal of Pharmacology and Experimental Therapeutics·Takato HiranitaJonathan L Katz
Jan 27, 2010·The Journal of Pharmacology and Experimental Therapeutics·Yan-Tong XuRae R Matsumoto
Aug 24, 2011·The Journal of Pharmacology and Experimental Therapeutics·Takato HiranitaJonathan L Katz
Aug 3, 2013·The Journal of Pharmacology and Experimental Therapeutics·Takato HiranitaJonathan L Katz
Jul 1, 2009·Expert Review of Clinical Pharmacology·Rae R Matsumoto
Apr 19, 2016·Journal of Drug and Alcohol Research·Yuko Yasui, Tsung-Ping Su
Mar 13, 2012·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Seshulatha JamalapuramBonnie A Avery
Oct 13, 2009·Hormones and Behavior·Vanya Quinones-Jenab, Shirzad Jenab
Jul 22, 2009·Pharmacology & Therapeutics·Tangui Maurice, Tsung-Ping Su
Dec 10, 2015·Behavioural Pharmacology·Jonathan L KatzTsung-Ping Su
Mar 3, 2009·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Marion ToussaintPatricia Melnyk
Sep 9, 2008·Bioorganic & Medicinal Chemistry Letters·Jianjing CaoAmy Hauck Newman
Mar 21, 2007·Progress in Neuro-psychopharmacology & Biological Psychiatry·Daniela Fukue FukushiroRoberto Frussa-Filho
Jan 12, 2012·Pharmacology, Biochemistry, and Behavior·Yan-Tong XuRae R Matsumoto
Oct 22, 2014·Expert Opinion on Therapeutic Targets·Shang-Yi A TsaiTsung-Ping Su
Jun 10, 2015·Journal of Receptor and Signal Transduction Research·Colin G Rousseaux, Stephanie F Greene
Jan 4, 2012·Physiology & Behavior·Katherine M SerafineAnthony L Riley

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.